-
Mashup Score: 3Ribociclib Plus Nonsteroidal Aromatase Inhibitor Extends iDFS in HR+/HER2– Early-Stage Breast Cancer - 1 month(s) ago
Ribociclib plus a nonsteroidal aromatase inhibitor bested nonsteroidal aromatase inhibitor therapy alone in terms of iDFS in early-stage breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Ribociclib Plus Nonsteroidal Aromatase Inhibitor Extends iDFS in HR+/HER2– Early-Stage Breast Cancer - 1 month(s) ago
Ribociclib plus a nonsteroidal aromatase inhibitor bested nonsteroidal aromatase inhibitor therapy alone in terms of iDFS in early-stage breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Ribociclib Plus Nonsteroidal Aromatase Inhibitor Extends iDFS in HR+/HER2– Early-Stage Breast Cancer - 2 month(s) ago
Ribociclib plus a nonsteroidal aromatase inhibitor bested nonsteroidal aromatase inhibitor therapy alone in terms of iDFS in early-stage breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
The AURKA inhibitor alisertib has emerged as an agent of particular note, demonstrating early signals of efficacy with a manageable safety profile for the treatment of patients with locally advanced or metastatic breast cancer whose disease is resistant to endocrine therapies.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
By. Stuart McIntosh, MDDate. November 03, 2023Stuart McIntosh, MD, Chief Medical Officer, initiated a study in the field of oncology. His work involved combining samuraciclib, a CDK7 inhibitor, with elacestrant, an oral Selective Estrogen Receptor Degrader (SERD), specifically for patients with CDK4/6 inhibitor-resi…
Source: oncologytube.comCategories: General Medicine News, Onc News and JournalsTweet
Ribociclib Plus Nonsteroidal Aromatase Inhibitor Extends iDFS in HR+/HER2– Early-Stage Breast Cancer. #oncology #breastcancer https://t.co/MY8H2Upfe8